HVTN 049

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine and a Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine in Healthy, HIV-1 Uninfected Adult Participants

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network (HVTN) December 01, 2003
Gag and Env DNA/PLG microparticles,Oligomeric gp140/MF59 DNA Env, gag B; Protein Env gp140 B
Gag and Env DNA/PLG microparticles DNA
Oligomeric gp140/MF59 Protein
USA 96